GET DAILY SIGNALSARS Pharmaceuticals (SPRY): Assessing the Feasibility of a +685% Move to $24
Key Takeaways
- The central target of $24 is based on the average of current analyst price targets, which cluster around $24–$25 across the four to six firms that publish numeric objectives.
- The most recent named targets span a wide $15–$30 range — Leerink Partners at $15 (September 8, 2026) and Cantor Fitzgerald at $30 (August 14, 2026) — with older targets having run as high as $40 (Roth Capital, September 2025).
- With the latest verified price near $3.05, reaching $24 would require a gain of roughly 685% — a very large move even by volatile biotech standards.
- The strongest support comes from neffy's first-mover position in needle-free anaphylaxis treatment, rapid revenue growth, and expanding international and payor access.
- The biggest risks are ongoing losses, rapid cash burn, downward revisions to revenue estimates, and a share price in a persistent downtrend.
- Readers can explore Major News, Today's Price Move, the Forecast, and Earnings pages for additional detail on this ticker.
- Investors seeking systematic, data-driven signals can also explore Trending AI Robots for automated market analysis.
Analyst Price Targets and Consensus View
The analyst price target picture for SPRY is unusually wide, reflecting genuine disagreement about how quickly neffy's commercial ramp will convert into profits. The most recently published, explicitly named objectives are Leerink Partners' $15 target (maintained with an Outperform rating in early September 2026 after being trimmed from $18) and Cantor Fitzgerald's $30 target (reiterated in August 2026). William Blair also maintains a Buy rating but does not publish a numeric target. Earlier coverage initiations include Roth Capital at $40 and Scotiabank at $30, both from 2025.
Third-party aggregators that track a broader pool of covering analysts report an average stock price target near $24–$25, within a $15–$30 range. That $24 average anchor — a rounded figure — is the central target used throughout this article. It is not an official published consensus, but a calculated mean of the verified current targets, and it sits far below the bullish outliers that once dominated the name. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified price for SPRY is approximately $3.05, with a 52-week range of $2.91 to $13.15. Reaching $24 would therefore require a gain of roughly 685% — a very large move that would essentially require the company to re-rate from a deeply depressed level back toward levels it traded at only a year ago. The stock currently trades below both its 50-day (around $4.77) and 200-day (around $7.56) moving averages, and the Zacks rating on the name is bearish.
Fundamentally, the company generated roughly $117 million in trailing revenue but remains unprofitable, with a trailing EPS (earnings per share) near -$2.18 and a net loss of about $215 million over the past twelve months. Full-year 2026 revenue is expected to grow to roughly $128 million. Reaching the $24 target would likely require sustained, accelerating neffy adoption, progress toward cash-flow breakeven, and a meaningful expansion of the valuation multiple the market is willing to pay.
What Could Support a Move Toward the Target
- First-mover needle-free franchise. neffy is the only approved needle-free epinephrine option for anaphylaxis, a differentiated position against traditional auto-injectors.
- Revenue momentum. Analysts project 2026 revenue growth of more than 50%, and the company beat revenue expectations in its June 2026 quarter.
- International expansion. Approvals in China and Australia (December 2025), a positive CHMP opinion for EURneffy 1mg (January 2026), and expected Canadian approval broaden the addressable market.
- Payor access. Progress with CVS Caremark, Anthem, and Aetna formularies supports broader prescription coverage.
- Competitive opening. A regulatory setback (an FDA deficiency letter) for a key rival has been cited by analysts as a potential tailwind for neffy adoption.
What Could Prevent the Target From Being Reached
- Persistent losses and cash burn. The company is not profitable and has been consuming cash rapidly, with leverage concerns on its balance sheet.
- Downward estimate revisions. Over the past 90 days, full-year 2026 revenue estimates were cut from about $139.7 million to $128.5 million, and 2027 estimates from about $245.7 million to $187.2 million.
- Earnings misses. The June 2026 quarter reported a -$0.63 EPS loss, missing the -$0.48 consensus estimate and triggering a one-day decline of about 7%.
- Bearish ratings. Weiss Ratings issued a sell-side downgrade in August 2026, and price targets across the Street have generally moved lower over the past year.
- Technical weakness. The stock sits near its 52-week low with a clearly defined downtrend, which can make sustained recovery difficult.
Technical Levels and Market Structure
SPRY's market structure is decidedly weak. The shares closed near $3.05, just above the 52-week low of $2.91, which now represents the primary support level to watch. A break below that level would open fresh downside risk. On the upside, the first meaningful resistance zone sits in the $3.66–$4.32 area, followed by the 50-day moving average near $4.77 and the 200-day moving average near $7.56. The psychological $10 and prior $13.15 high are far above current levels and would need to be cleared well before the $24 target becomes technically relevant. The relative strength index near the mid-30s suggests the stock is oversold, but oversold conditions alone do not reverse a downtrend. From what I see, the technical picture reinforces the need for fundamental catalysts to drive any meaningful recovery.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm and was not disclosed in all cases. Given the wide $15–$40 dispersion, investors should treat the central target as a directional reference rather than a near-term milestone. The most important near-term catalyst is the third-quarter 2026 earnings report scheduled for November 5, 2026, where consensus expects a loss near -$0.34 per share on revenue of about $42 million. Beyond earnings, investors should watch payor formulary decisions, international launch progress, cash runway updates, and any further analyst target revisions, which have been trending lower. I’m watching this closely as the earnings date approaches.
Exploring AI Daily Buy/Sell Signals
In my own research process, Tickeron's AI Daily Buy/Sell Signals have proven useful for monitoring names like this. The tool uses artificial intelligence to continuously track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that adapt to shifting market conditions, technical behavior, and momentum. For a volatile stock such as SPRY, where sentiment can turn quickly, these signals offer an additional layer of context alongside traditional analysis without replacing fundamental work.
Final Assessment
Can SPRY reach $24? The arithmetic says the move would be enormous — roughly 685% above the latest verified price near $3.05 — and the current analyst range of $15–$30 shows the Street itself is far from unanimous. The bullish case rests on a genuinely differentiated, first-to-market product in neffy, accelerating revenue, and expanding international and payor access. The bearish case points to persistent losses, rapid cash burn, downward estimate revisions, and a stock mired near multi-year lows. The $24 central target reflects the average of current analyst objectives rather than a guarantee, and reaching it would likely require both sustained commercial execution and a substantial re-rating in investor sentiment. Investors should watch the November 5 earnings report, cash runway disclosures, and any shift in analyst revisions as the most telling indicators of whether such a recovery is taking shape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
SPRY in -16.67% downward trend, sliding for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SPRY declined for three days, in 235 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRY turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
The Aroon Indicator for SPRY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 232 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.242) is normal, around the industry mean (3.051). P/E Ratio (-1.399) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement